Alcon (SIX/NYSE: ALC), the global leader in eye care dedicated to enhancing vision, has unveiled the final data from its Vivity® Registry Study, which tracked real-world patient experiences for up to 12 months following cataract surgery with the implantation of either AcrySof® IQ Vivity® or AcrySof® IQ Vivity® Toric presbyopia-correcting intraocular lens (PCIOL). The data, derived from over 900 cataract patients, highlights the sustained clinical effectiveness, high patient satisfaction, and reduced dependence on spectacles (eyeglasses). It also suggests that AcrySof® IQ Vivity® can effectively serve a broad spectrum of patients, offering surgeons and patients additional treatment choices.

Sunil Vasanth, VP, Europe Surgical Franchise at Alcon, expressed pride in the innovation of AcrySof® IQ Vivity®, a groundbreaking non-diffractive extended depth of focus IOL developed using Alcon's proprietary X-WAVETM technology, which manipulates light without diffracting it. He emphasized that real-world registry data provides surgeons with the assurance that Vivity's performance endures over time. Importantly, this data includes patients with common mild comorbidities such as glaucoma, dry eye, and retinopathy/maculopathy.

The Vivity® Registry Study3, conducted across 41 sites in eight countries (Australia, Belgium, Germany, New Zealand, the Netherlands, Portugal, Spain, and the United Kingdom), produced the following key findings:3

• Three-quarters of patients reported no difficulties with their vision for everyday activities.
• A vast majority (92%) of patients were satisfied with their vision.
• Over 91% of patients reported no halos, glares, or starbursts, which are common visual disturbances associated with diffractive IOLs.
• The study observed excellent binocular distance and intermediate uncorrected visual acuity, with mean Snellen visual acuity values of 20/20 and 20/25, respectively.
• More than 78% and 88% of patients reported no longer needing glasses for viewing at arm's length and long distances, respectively.

These results, along with additional data, are being discussed in sessions featuring renowned surgeons at the 41st Congress of the European Society of Cataract and Refractive Surgeons (ESCRS) in Vienna, Austria. For a comprehensive overview of relevant abstracts, please visit MyAlconatESCRS.com.

AcrySof® IQ Vivity®, a non-diffractive IOL, employs Alcon's proprietary Wavefront-Shaping X-WAVETM technology, an advanced optical principle that stretches and shifts light without diffracting it. As a result, it addresses the unmet medical need for excellent distance, intermediate, and functional near vision while minimizing visual disturbances.

Vision is a top concern for individuals as they age, with a Global Alcon Survey indicating that vision ranks second only to memory as the most important quality of aging (83%). For those diagnosed with cataracts, vision is their primary concern, and post-surgery, 81% of patients who received any PCIOL reported an improved quality of life. Moreover, 69% of respondents, including those without a cataract diagnosis, expressed a desire to be free from glasses. Among those awaiting cataract surgery, 75% indicated a willingness to pay for a lens that eliminates the need for spectacles.

Vision plays a pivotal role in enhancing the quality of life as individuals age, and AcrySof® IQ Vivity® can help meet patient expectations for performance, quality of life, and spectacle independence.

Note: AcrySof® IQ Vivity® and AcrySof® IQ Vivity® Toric may not be approved in all markets; please consult your Alcon representative for information on availability in your local market. Refer to the relevant product documentation for a complete list of indications, contraindications, and warnings.

 

Source: businesswire.com

Report Abuse